Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | ENO1 | P06733 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfonet SCHEMBL15612 | 0.91 | — | — | |
| Fosfonet SCHEMBL27988277 | 0.89 | MEN1 (0.74) | MEN1LMNAHPGDTSHRBLM | |
| Fosfonet SCHEMBL28151124 | 0.88 | — | — | |
| Fosfonet SCHEMBL2801407 | 0.88 | — | — | |
| Fosfonet SCHEMBL26676054 | 0.88 | — | — | |
| Fosfonet SCHEMBL11026013 | 0.88 | — | — | |
| Fosfonet SCHEMBL9162319 | 0.88 | — | — | |
| Fosfonet SCHEMBL4607410 | 0.88 | MEN1 (0.93) | MEN1LMNAHPGDTSHRBLM | |
| Fosfonet SCHEMBL15510455 | 0.88 | MEN1 (0.93) | MEN1LMNAHPGDTSHRBLM | |
| Fosfonet SCHEMBL26676053 | 0.88 | MEN1 (0.93) | MEN1LMNAHPGDTSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040219671-A1 | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219671-A1 | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) | PARK7, SNCA, PINK1 | MEN1 3278/4885LMNA 4051/4885HPGD 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.